Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer
Effector regulatory T cells (eTregs) are novel immunotargets for HRD ovarian cancer and combining PARP inhibitors with CCR8 blockade enhances therapeutic efficacy
Identifying eTregs as a target in HRD ovarian cancer can improve therapeutic outcomes and guide the combination of PARP inhibitors with immunotherapy, offering a promising strategy for patients who are refractory to current treatments.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements